AAAAAA

   
Results: 1-25 | 26-33
Results: 1-25/33
ARCHITECTURAL PATTERNS IN BRANCHING MORPHOGENESIS IN THE KIDNEY
Authors: ALAWQATI Q GOLDBERG MR
Citation: Q. Alawqati et Mr. Goldberg, ARCHITECTURAL PATTERNS IN BRANCHING MORPHOGENESIS IN THE KIDNEY, Kidney international, 54(6), 1998, pp. 1832-1842
PHARMACOKINETICS (PK) OF INTRAVENOUS (IV) RIZATRIPTAN (R) IN HEALTHY FEMALES
Authors: ROGERS JD LEE Y GOLDBERG MR ERMLICH S BRUCKER MJ MCLOUGHLIN DA OLAH TV
Citation: Jd. Rogers et al., PHARMACOKINETICS (PK) OF INTRAVENOUS (IV) RIZATRIPTAN (R) IN HEALTHY FEMALES, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 22-22
EFFECTS OF RIZATRIPTAN ON BLOOD-PRESSURE IN HYPERTENSIVE PATIENTS
Authors: NOVECK RJ BIALY GP BRADSTREET TE GAGLIANO KD GOLDBERG MR
Citation: Rj. Noveck et al., EFFECTS OF RIZATRIPTAN ON BLOOD-PRESSURE IN HYPERTENSIVE PATIENTS, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 48-48
LACK OF PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTION BETWEEN RIZATRIPTAN AND PAROXETINE
Authors: GOLDBERG MR LOWRY R MUSSON DG BIRK KL FISHER A DEPUY ME SHADLE CR
Citation: Mr. Goldberg et al., LACK OF PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTION BETWEEN RIZATRIPTAN AND PAROXETINE, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 54-54
PHARMACOKINETICS OF RIZATRIPTAN IN PATIENTS WITH MILD-MODERATE HEPATIC INSUFFICIENCY
Authors: GOLDBERG MR LEE Y PANEBIANCO D NOVECK RJ BRUCKER MJ MCLOUGHLIN DA OLAH TV SHADLE CR
Citation: Mr. Goldberg et al., PHARMACOKINETICS OF RIZATRIPTAN IN PATIENTS WITH MILD-MODERATE HEPATIC INSUFFICIENCY, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 55-55
ENDOTHELIAL-CELL TARGETING DURING RENAL DEVELOPMENT - USE OF MONOCLONAL-ANTIBODIES
Authors: OLIVER JA GOLDBERG MR ALAWQATI Q
Citation: Ja. Oliver et al., ENDOTHELIAL-CELL TARGETING DURING RENAL DEVELOPMENT - USE OF MONOCLONAL-ANTIBODIES, American journal of physiology. Renal, fluid and electrolyte physiology, 41(2), 1997, pp. 153-159
SPATIAL AND TEMPORAL EXPRESSION OF CELL-SURFACE MOLECULES DURING NEPHROGENESIS
Authors: GOLDBERG MR BARASCH J SHIFTEH A DAGATI V OLIVER JA HU C ALAWQATI Q
Citation: Mr. Goldberg et al., SPATIAL AND TEMPORAL EXPRESSION OF CELL-SURFACE MOLECULES DURING NEPHROGENESIS, American journal of physiology. Renal, fluid and electrolyte physiology, 41(1), 1997, pp. 79-86
DUP-532, AN ANGIOTENSIN-II RECEPTOR ANTAGONIST - FIRST ADMINISTRATIONAND COMPARISON WITH LOSARTAN
Authors: GOLDBERG MR LO MW CHRIST DD CHIOU R FURTEK CI AMIT O CARIDES A BIOLLAZ J PIGUET V NUSSBERGER J BRUNNER HR
Citation: Mr. Goldberg et al., DUP-532, AN ANGIOTENSIN-II RECEPTOR ANTAGONIST - FIRST ADMINISTRATIONAND COMPARISON WITH LOSARTAN, Clinical pharmacology and therapeutics, 61(1), 1997, pp. 59-69
ISOLATION OF A PROTEIN INVOLVED IN TARGETING ENDOTHELIAL-CELLS DURINGKIDNEY DEVELOPMENT
Authors: HU C OLIVER JA GOLDBERG MR ALAWQATI Q
Citation: C. Hu et al., ISOLATION OF A PROTEIN INVOLVED IN TARGETING ENDOTHELIAL-CELLS DURINGKIDNEY DEVELOPMENT, Molecular biology of the cell, 7, 1996, pp. 1792-1792
FORMATION OF BLOOD-VESSELS DURING LUNG DEVELOPMENT
Authors: GOLDBERG MR SHIFTEH A ALAWQATI Q
Citation: Mr. Goldberg et al., FORMATION OF BLOOD-VESSELS DURING LUNG DEVELOPMENT, Pediatric research, 39(4), 1996, pp. 2301-2301
NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONISTS - THE NEXT-GENERATION IN ANTIHYPERTENSIVE THERAPY
Authors: WEXLER RR GREENLEE WJ IRVIN JD GOLDBERG MR PRENDERGAST K SMITH RD TIMMERMANS PBMWM
Citation: Rr. Wexler et al., NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONISTS - THE NEXT-GENERATION IN ANTIHYPERTENSIVE THERAPY, Journal of medicinal chemistry, 39(3), 1996, pp. 625-656
PHENOBARBITAL MINIMALLY ALTERS PLASMA-CONCENTRATIONS OF LOSARTAN AND ITS ACTIVE METABOLITE E-3174
Authors: GOLDBERG MR LO MW DEUTSCH PJ WILSON SE MCWILLIAMS EJ MCCREA JB
Citation: Mr. Goldberg et al., PHENOBARBITAL MINIMALLY ALTERS PLASMA-CONCENTRATIONS OF LOSARTAN AND ITS ACTIVE METABOLITE E-3174, Clinical pharmacology and therapeutics, 59(3), 1996, pp. 268-274
FIRST-DOSE EFFECTS OF LOSARTAN VS CAPTOPRIL IN THIAZIDE-TREATED HYPERTENSIVE PATIENTS
Authors: GOLDBERG MR STAUB T ERMLICH S BLUM R LEWIS G
Citation: Mr. Goldberg et al., FIRST-DOSE EFFECTS OF LOSARTAN VS CAPTOPRIL IN THIAZIDE-TREATED HYPERTENSIVE PATIENTS, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 44-44
KETOCONAZOLE DOES NOT EFFECT THE SYSTEMIC CONVERSION OF LOSARTAN TO E-3174
Authors: MCCREA JB LO MW FURTEK CI RITTER MA CARIDES A WALDMAN SA BJORNSSON TD GOLDBERG MR
Citation: Jb. Mccrea et al., KETOCONAZOLE DOES NOT EFFECT THE SYSTEMIC CONVERSION OF LOSARTAN TO E-3174, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 44-44
DIFFERENTIAL-EFFECTS OF ORAL LOSARTAN AND ENALAPRIL ON LOCAL VENOUS AND SYSTEMIC PRESSOR-RESPONSES TO ANGIOTENSIN-I AND ANGIOTENSIN-II IN HEALTHY-MEN
Authors: GOLDBERG MR DEMEY C WROBLEWSKI JM LI Q SCHROETER V BELZ GG
Citation: Mr. Goldberg et al., DIFFERENTIAL-EFFECTS OF ORAL LOSARTAN AND ENALAPRIL ON LOCAL VENOUS AND SYSTEMIC PRESSOR-RESPONSES TO ANGIOTENSIN-I AND ANGIOTENSIN-II IN HEALTHY-MEN, Clinical pharmacology and therapeutics, 59(1), 1996, pp. 72-82
PHASE-I CLINICAL-STUDY OF THE RECOMBINANT ONCOTOXIN TP40 IN SUPERFICIAL BLADDER-CANCER
Authors: GOLDBERG MR HEIMBROOK DC RUSSO P SAROSDY MF GREENBERG RE GIANTONIO BJ LINEHAN WM WALTHER M FISHER HAG MESSING E CRAWFORD ED OLIFF AI PASTAN IH
Citation: Mr. Goldberg et al., PHASE-I CLINICAL-STUDY OF THE RECOMBINANT ONCOTOXIN TP40 IN SUPERFICIAL BLADDER-CANCER, Clinical cancer research, 1(1), 1995, pp. 57-61
PLASMA ACTIVE RENIN (AR) GLYCOFORM PROFILE AFTER ACUTE AND CHRONIC STIMULATION WITH LOSARTAN (L)
Authors: OPSAHL JA GOLDBERG MR KATZ SA
Citation: Ja. Opsahl et al., PLASMA ACTIVE RENIN (AR) GLYCOFORM PROFILE AFTER ACUTE AND CHRONIC STIMULATION WITH LOSARTAN (L), Journal of the American Society of Nephrology, 6(3), 1995, pp. 646-646
EFFECT OF ACUTE AND CHRONIC LOSARTAN THERAPY ON ACTIVE AND INACTIVE RENIN AND ACTIVE RENIN GLYCOFORMS
Authors: OPSAHL JA GOLDBERG MR KATZ SA
Citation: Ja. Opsahl et al., EFFECT OF ACUTE AND CHRONIC LOSARTAN THERAPY ON ACTIVE AND INACTIVE RENIN AND ACTIVE RENIN GLYCOFORMS, American journal of hypertension, 8(11), 1995, pp. 1090-1098
EFFECT OF MULTIPLE DOSES OF LOSARTAN ON THE PHARMACOKINETICS OF SINGLE DOSES OF DIGOXIN IN HEALTHY-VOLUNTEERS
Authors: DESMET M SCHOORS DF DEMEYER G VERBESSELT R GOLDBERG MR FITZPATRICK V SOMERS G
Citation: M. Desmet et al., EFFECT OF MULTIPLE DOSES OF LOSARTAN ON THE PHARMACOKINETICS OF SINGLE DOSES OF DIGOXIN IN HEALTHY-VOLUNTEERS, British journal of clinical pharmacology, 40(6), 1995, pp. 571-575
BIOCHEMICAL EFFECTS OF LOSARTAN, A NONPEPTIDE ANGIOTENSIN-II RECEPTORANTAGONIST, ON THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS
Authors: GOLDBERG MR BRADSTREET TE MCWILLIAMS EJ TANAKA WK LIPERT S BJORNSSON TD WALDMAN SA OSBORNE B PIVADORI L LEWIS G BLUM R HERMAN T ABRAHAM PA HALSTENSON CN LO MW LU H SPECTOR R
Citation: Mr. Goldberg et al., BIOCHEMICAL EFFECTS OF LOSARTAN, A NONPEPTIDE ANGIOTENSIN-II RECEPTORANTAGONIST, ON THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS, Hypertension, 25(1), 1995, pp. 37-46
ABSENCE OF A PHARMACOKINETIC INTERACTION BETWEEN LOSARTAN AND HYDROCHLOROTHIAZIDE
Authors: MCCREA JB LO MW TOMASKO L LIN CC HSIEH JYK CAPRA NL GOLDBERG MR
Citation: Jb. Mccrea et al., ABSENCE OF A PHARMACOKINETIC INTERACTION BETWEEN LOSARTAN AND HYDROCHLOROTHIAZIDE, Journal of clinical pharmacology, 35(12), 1995, pp. 1200-1206
LOSARTAN DOES NOT AFFECT THE PHARMACOKINETICS AND PHARMACODYNAMICS OFWARFARIN
Authors: KONG ANT TOMASKO L WALDMAN SA OSBORNE B DEUTSCH PJ GOLDBERG MR BJORNSSON TD
Citation: Ant. Kong et al., LOSARTAN DOES NOT AFFECT THE PHARMACOKINETICS AND PHARMACODYNAMICS OFWARFARIN, Journal of clinical pharmacology, 35(10), 1995, pp. 1008-1015
EFFECTS OF CIMETIDINE ON PHARMACOKINETICS AND PHARMACODYNAMICS OF IOSARTAN, AN AT(1)-SELECTIVE NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST
Authors: GOLDBERG MR LO MW BRADSTREET TE RITTER MA HOGLUND P
Citation: Mr. Goldberg et al., EFFECTS OF CIMETIDINE ON PHARMACOKINETICS AND PHARMACODYNAMICS OF IOSARTAN, AN AT(1)-SELECTIVE NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST, European Journal of Clinical Pharmacology, 49(1-2), 1995, pp. 115-119
PHARMACOKINETICS OF LOSARTAN, AN ANGIOTENSIN-II RECEPTOR ANTAGONIST, AND ITS ACTIVE METABOLITE EXP3174 IN HUMANS
Authors: LO MW GOLDBERG MR MCCREA JB LU H FURTEK CI BJORNSSON TD
Citation: Mw. Lo et al., PHARMACOKINETICS OF LOSARTAN, AN ANGIOTENSIN-II RECEPTOR ANTAGONIST, AND ITS ACTIVE METABOLITE EXP3174 IN HUMANS, Clinical pharmacology and therapeutics, 58(6), 1995, pp. 641-649
NONRUPTURED ABDOMINAL AORTIC-ANEURYSM - 6-YEAR FOLLOW-UP RESULTS FROMTHE MULTICENTER PROSPECTIVE CANADIAN ANEURYSM STUDY
Authors: JOHNSTON KW KALMAN PG AMELI FM EVANS G MCPHAIL NV SLADEN JG AUSTERWEIL A AU HH BAIRD RJ BALACHANDRA VK BARBER GG BASIAN H BLUNDELL PE BROWN PM BRUNEAU L CALLAGHAN JC CARROLL SE CHIU CJ DEROSE G DOOBAY BS DOUVILLE Y DOWNS AR DUNN RS DUTTON JW ERRET LE FONG HMT FRY PD GELFAND ET GOLDBACH MM GOLDBERG MR GOLDSTEIN AS GOODING JT GRANT KC GUNSTENSEN J HARRIS KA HEIDE AR HILDEBRAND H HUNTING MC HYATT HJ JAMIESON WG KING WL LAURENDEAU F LITHERLAND HK MACKEAN GL MADDISON GD MAGGISANO R MEADS GE MICHALSKI AH MODREY DL MOFFAT RC MOONJE VB MORIN JE MOSAKOSKI JF MULDER DS MURPHY FG NOEL HP ODWYER MG PARISI A PERERA NV PISESKY W PROVAN JL RANKIN JA RITCHIE RH SALVIAN AJ SCOBIE TK SCOTT HJ SHAH PA STERNS LP SYMES JF TANNER JR WALKER PM WEISEL RD WELLINGTON JL WOOSTER DL YOU CK
Citation: Kw. Johnston et al., NONRUPTURED ABDOMINAL AORTIC-ANEURYSM - 6-YEAR FOLLOW-UP RESULTS FROMTHE MULTICENTER PROSPECTIVE CANADIAN ANEURYSM STUDY, Journal of vascular surgery, 20(2), 1994, pp. 163-170
Risultati: 1-25 | 26-33